Granite Point Capital Management’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

Granite Point Capital Management’s Portfolio OMED Stock Details OMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-79,650	Closed	-$910K	–	111
2016 Q3	$910K	Sell	79,650 -12,200	-13%	-$142K	0.36%	52
2016 Q2	$1.13M	Buy	+91,850	New	+$1.11M	0.49%	36
2014 Q2	–	Sell	-36,000	Closed	-$1.21M	–	119
2014 Q1	$1.21M	Sell	36,000 -8,100	-18%	-$273K	0.87%	34
2013 Q4	$1.3M	Buy	+44,100	New	+$808K	0.22%	52

Other funds holding OMED

ASP

Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

IHM

Iguana Healthcare Management New York $152M AUM 48.74% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Granite Point Capital Management's OMED Position: Q4 2016 in Review

Granite Point Capital Management sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q4 2016, closing a stake of 79,650 shares — an estimated $910K sold.

Granite Point Capital Management first reported a position in OMED in Q4 2013 and held it in 4 quarters. The position peaked at $1.3M in Q4 2013. 86 funds tracked by Wall St. Rank hold OMED as of Q4 2016.

Granite Point Capital Management reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q4 2016 after selling out during the quarter.
Granite Point Capital Management sold 79,650 OncoMed Pharmaceuticals, Inc. shares in Q4 2016, an estimated $910K.
Granite Point Capital Management first reported a position in OncoMed Pharmaceuticals, Inc. in Q4 2013 and held it in 4 quarters.
Granite Point Capital Management's OncoMed Pharmaceuticals, Inc. position peaked at $1.3M in Q4 2013.
86 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q4 2016.

Based on Granite Point Capital Management's 13F filing for Q4 2016, filed 7 Feb 2017.